This company listing is no longer active
Eisai Past Earnings Performance
Past criteria checks 0/6
Key information
-5.1%
Earnings growth rate
-5.1%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 4.7% |
Return on equity | 3.4% |
Net Margin | 3.6% |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Eisai makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 737,098 | 26,705 | 373,875 | 169,848 |
30 Sep 22 | 752,500 | 32,233 | 382,752 | 173,324 |
30 Jun 22 | 741,594 | 32,690 | 374,428 | 168,422 |
31 Mar 22 | 756,226 | 47,954 | 356,847 | 171,738 |
31 Dec 21 | 712,935 | 57,311 | 317,150 | 165,418 |
30 Sep 21 | 691,250 | 62,508 | 293,153 | 162,699 |
30 Jun 21 | 679,253 | 59,855 | 282,369 | 161,584 |
31 Mar 21 | 645,942 | 42,119 | 272,568 | 150,299 |
31 Dec 20 | 707,888 | 93,682 | 271,476 | 145,248 |
30 Sep 20 | 713,400 | 120,571 | 261,973 | 139,628 |
30 Jun 20 | 707,203 | 124,523 | 253,516 | 141,217 |
31 Mar 20 | 695,621 | 121,767 | 248,554 | 140,116 |
31 Dec 19 | 661,646 | 96,659 | 244,091 | 146,367 |
30 Sep 19 | 631,974 | 57,725 | 239,503 | 147,863 |
30 Jun 19 | 643,531 | 72,747 | 233,180 | 140,143 |
31 Mar 19 | 642,834 | 63,386 | 223,798 | 144,844 |
31 Dec 18 | 627,367 | 63,714 | 212,469 | 139,100 |
30 Sep 18 | 625,106 | 65,679 | 195,229 | 138,461 |
30 Jun 18 | 611,499 | 54,347 | 186,198 | 140,514 |
31 Mar 18 | 600,054 | 51,845 | 179,915 | 139,579 |
31 Dec 17 | 569,814 | 29,048 | 178,312 | 134,955 |
30 Sep 17 | 554,276 | 30,269 | 178,090 | 123,639 |
30 Jun 17 | 544,027 | 29,425 | 176,249 | 119,503 |
31 Mar 17 | 539,097 | 39,358 | 175,633 | 112,478 |
31 Dec 16 | 530,696 | 55,031 | 175,240 | 110,471 |
30 Sep 16 | 542,313 | 71,812 | 178,825 | 114,420 |
30 Jun 16 | 545,602 | 69,227 | 182,036 | 115,750 |
31 Mar 16 | 547,922 | 54,933 | 188,227 | 122,307 |
Quality Earnings: EII0 has a large one-off gain of ¥13.4B impacting its last 12 months of financial results to December 31 2022.
Growing Profit Margin: EII0's current net profit margins (3.6%) are lower than last year (8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EII0's earnings have declined by 5.1% per year over the past 5 years.
Accelerating Growth: EII0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EII0 had negative earnings growth (-53.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.1%).
Return on Equity
High ROE: EII0's Return on Equity (3.4%) is considered low.